Skip to content
Home » Pharmaceutical » BioNTech

BioNTech

scientist in laboratory

mRNA vaccine for pancreatic cancer — excellent long-term results

Recent long-term clinical trial data reveals the personalized mRNA vaccine, cevumeran, elicits a lasting immune response in pancreatic cancer patients, significantly improving recurrence-free survival. The phase 2 trial explores cevumeran’s combined efficacy with chemotherapy, as this approach shows potential to revolutionize treatment for this hard-to-treat cancer, underscoring mRNA vaccines’ role in advancing medical treatments.

doctors and nurses in a hospital

New mRNA vaccine for pancreatic cancer enters phase 2 trials

A new personalized mRNA vaccine for pancreatic cancer, cevumeran, has shown promise in a phase 1 trial and is advancing to a larger phase 2 trial. It works by inducing an immune response against specific antigens in each patient’s tumor, offering hope for a disease with typically poor prognosis. Developed by BioNTech, cevumeran complements standard treatments like surgery and chemotherapy, potentially increasing overall success rates.

flu COVID-19 mRNA vaccine

Combination flu and COVID mRNA vaccine starting clinical trials

Pfizer and BioNTech have announced the start of a phase 1 clinical trial for a new mRNA vaccine that prevents both the flu and COVID-19. The new vaccine targets these two severe respiratory diseases with one jab.

Although during the past three years we have focused on the COVID-19 pandemic, the seasonal flu is also a dangerous disease. During the 2019-2020 flu season, the last one before COVID-19 mitigation efforts reduced the risk of flu, 390,000 Americans were hospitalized from the flu. And over 25,000 died.

So, a new mRNA vaccine (with all of its advantages to tailor the vaccine to the key antigens on the virus) that combines both flu and COVID-19 can be an effective weapon against these two diseases. In a couple of years, if all goes well, we will be able to get a season flu-COVID-19 mRNA vaccine that has been manufactured for the season’s prevalent variants of both diseases.

Let’s take a look at what we know about this new vaccine and the phase 1 clinical trial.

Read More »Combination flu and COVID mRNA vaccine starting clinical trials